United Kingdom

People: Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

19 Jul 2019
Change (% chg)

$0.03 (+3.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Burow, Kristina 

Ms.Kristina M Burow is board of directors since October 2015. Ms. Burow has served as Managing Director with ARCH Venture Partners since November 2011 and previously held positions of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow also currently serves on the boards of directors of Vividion Therapeutics, Inc., a biotechnology company, Lycera Corp., a biopharmaceutical company, BlackThorn Therapeutics, Inc., a biopharmaceutical company, Metacrine, Inc., a biotechnology company, Scholar Rock, Inc., a biotechnology company, Unity Biotechnology, a biotechnology company, AgBiome Inc., a biotechnology company, AgTech Accelerator, an agricultural technology startup accelerator, and Vir Biotechnology Inc., a biotechnology company. She previously was a co-founder and member of the board of directors of Receptos, Inc., a public pharmaceutical company, prior to its acquisition by Celgene Corporation, and of Sapphire Energy, Inc., an energy company. Ms. Burow has participated in a number of other ARCH portfolio companies including Kythera, Siluria Technologies, an energy company, and Ikaria, a biotechnology company acquired by Madison Dearborn. Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a B.A. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --